Fabrication and Characterization of Tumor Nano-Lysate as a Preventative Vaccine for Breast Cancer

Dombroski, Jenna A.; Jyotsana, Nidhi; Crews, Davis W; Zhang, Zhenjiang; King, Michael R.

doi:10.1021/acs.langmuir.0c00947

Cited by 12 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Sipuleucel-T, an FDA-approved cancer vaccine (albeit with limited efficacy) 221 , utilizes recombinant antigens specific to the tumour type. Although the drugs are not yet in the clinic, other groups have also developed synthetic peptides and tumour lysates with the ultimate goal of patient personalization [223][224][225] . NPs can protect these antigens from degradation, improve the likelihood that they are presented to target immune cells and reduce off-target effects.…”

Section: Nps For Immunotherapymentioning

confidence: 99%

Engineering precision nanoparticles for drug delivery

Mitchell

Billingsley

Haley

et al. 2020

Nat Rev Drug Discov

3,588

2,814

View full text Add to dashboard Cite

In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.

show abstract

Section: Nps For Immunotherapymentioning

confidence: 99%

Engineering precision nanoparticles for drug delivery

Mitchell

Billingsley

Haley

et al. 2020

Nat Rev Drug Discov

3,588

2,814

View full text Add to dashboard Cite

show abstract

“…A variety of vaccine therapies are also under investigation supporting the immune modulatory autologous system against breast cancer [ 266 ]. Interestingly, tumor nano lysates (TNLs) derived from cancer cells as a result of TRAIL and fluid sheer stress are under investigation in a pilot in vivo study as a preventive vaccine for TNBC [ 267 ].…”

Section: Strategies To Improve Dr Agonists In Patients With Breast Ca...mentioning

confidence: 99%

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

Kundu

Greer

Dine

et al. 2022

Cells

View full text Add to dashboard Cite

The tumor necrosis factor (TNF) superfamily member TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells via death receptor (DR) activation with little toxicity to normal cells or tissues. The selectivity for activating apoptosis in cancer cells confers an ideal therapeutic characteristic to TRAIL, which has led to the development and clinical testing of many DR agonists. However, TRAIL/DR targeting therapies have been widely ineffective in clinical trials of various malignancies for reasons that remain poorly understood. Triple negative breast cancer (TNBC) has the worst prognosis among breast cancers. Targeting the TRAIL DR pathway has shown notable efficacy in a subset of TNBC in preclinical models but again has not shown appreciable activity in clinical trials. In this review, we will discuss the signaling components and mechanisms governing TRAIL pathway activation and clinical trial findings discussed with a focus on TNBC. Challenges and potential solutions for using DR agonists in the clinic are also discussed, including consideration of the pharmacokinetic and pharmacodynamic properties of DR agonists, patient selection by predictive biomarkers, and potential combination therapies. Moreover, recent findings on the impact of TRAIL treatment on the immune response, as well as novel strategies to address those challenges, are discussed.

show abstract

“…The subsequent physical treatment of tumor cells, such as sonication, is optionally introduced to facilitate the homogeneity of the prepared TCLs. Nano-scale TCLs could be obtained using only sonication ( Figure 2 B) [ 29 ]. Additionally, ultraviolet (UV) irradiation is also commonly used to prepare TCLs by inducing immunogenic cell death (ICD) ( Figure 2 C) [ 30 ].…”

Section: Preparation Of Tumor Cell Lysatesmentioning

confidence: 99%

Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates

Seong

Kim

2022

Pharmaceutics

View full text Add to dashboard Cite

Tumor cell lysates (TCLs) are a good immunogenic source of tumor-associated antigens. Since whole necrotic TCLs can enhance the maturation and antigen-presenting ability of dendritic cells (DCs), multiple strategies for the exogenous delivery of TCLs have been investigated as novel cancer immunotherapeutic solutions. The TCL-mediated induction of DC maturation and the subsequent immunological response could be improved by utilizing various material-based carriers. Enhanced antitumor immunity and cancer vaccination efficacy could be eventually achieved through the in vivo administration of TCLs. Therefore, (1) important engineering methodologies to prepare antigen-containing TCLs, (2) current therapeutic approaches using TCL-mediated DC activation, and (3) the significant sequential mechanism of DC-based signaling and stimulation in adaptive immunity are summarized in this review. More importantly, the recently reported developments in biomaterial-based exogenous TCL delivery platforms and co-delivery strategies with adjuvants for effective cancer vaccination and antitumor effects are emphasized.

show abstract

Fabrication and Characterization of Tumor Nano-Lysate as a Preventative Vaccine for Breast Cancer

Cited by 12 publications

References 43 publications

Engineering precision nanoparticles for drug delivery

Engineering precision nanoparticles for drug delivery

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates

Contact Info

Product

Resources

About